

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 August 2020 (06.08.2020)



(10) International Publication Number
WO 2020/160465 A1

- (51) **International Patent Classification:**
A61P 19/02 (2006.01) *C07K 16/28* (2006.01)
- (21) **International Application Number:**
PCT/US2020/016203
- (22) **International Filing Date:**
31 January 2020 (31.01.2020)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
- | | | |
|------------|-------------------------------|----|
| 62/799,698 | 31 January 2019 (31.01.2019) | US |
| 62/851,474 | 22 May 2019 (22.05.2019) | US |
| 62/935,395 | 14 November 2019 (14.11.2019) | US |
| 19306553.9 | 03 December 2019 (03.12.2019) | EP |

(71) **Applicants:** **SANOFI BIOTECHNOLOGY** [FR/FR]; 54, rue La Boétie, 75008 Paris (FR). **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **VAN AEDELSBERG, Janet** [US/US]; 420 Riverside Drive, New York, NY 10025 (US).

(72) **Inventors:** **BARET-CORMEL, Lydie**; c/o Sanofi, 54, rue La Boétie, 75008 Paris (FR). **MOMTAHEN, Tanya**; 207 Susan Circle North, North Wales, PA 02421 (US). **FIGORE, Stefano**; c/o Sanofi, 55 Corporate Drive, Mail-Code 55A-505A, Bridgewater, NJ 08807 (US).

(74) **Agent:** **VELEMA, James, H.** et al.; Lathrop GPM LLP, 28 State Street, Boston, MA 02109 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) **Title:** ANTI-IL-6 RECEPTOR ANTIBODY FOR TREATING JUVENILE IDIOPATHIC ARTHRITIS

FIG. 1



(57) **Abstract:** The present disclosure provides compositions and methods of treating and improving the symptoms of systemic juvenile idiopathic arthritis and polyarticular-course juvenile idiopathic arthritis using an antibody that specifically binds human interleukin-6 receptor (IL-6R).

WO 2020/160465 A1